Additionally, combination treatment with A452 and BTZ or CFZ synergistically decreased cell viability and consequently enhanced apoptosis in both BTZ-sensitive and BTZ-resistant MM cells. The gene discussed is CASC3; the disease is Miyoshi myopathy.